Evidence map›Paper›PMID 29643185›Full record

ArticleThe Journal of experimental medicine2018

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.

Reina Nagase, Daichi Inoue, Alessandro Pastore, Takeshi Fujino, Hsin-An Hou, Norimasa Yamasaki, Susumu Goyama, Makoto Saika, Akinori Kanai, Yasuyuki Sera and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.Current hematologic malignancy reports · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Humanized mouse models in MDS.Cell death & disease · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Reina NagaseDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Daichi InoueDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan inoued@mskcc.org.
Alessandro PastoreHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0002-3621-4807
Takeshi FujinoDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hsin-An HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Norimasa YamasakiDepartment of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Susumu GoyamaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Makoto SaikaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akinori KanaiDepartment of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yasuyuki SeraDepartment of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Sayuri HorikawaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasunori OtaDepartment of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shuhei AsadaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasutaka HayashiDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kimihito Cojin KawabataDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Reina TakedaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hwei-Fang TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Hiroaki HondaDepartment of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.
Toshio KitamuraDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan kitamura@ims.u-tokyo.ac.jp.ORCID 0000-0001-7855-1767

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HematopoiesisAdultAnimalsBase SequenceCell Transformation, NeoplasticEpigenesis, GeneticGene Expression Regulation, LeukemicGene Knock-In TechniquesGenome, HumanHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHistonesHumansLeukemiaLeukemia, Myeloid, AcuteMiceASXL1 protein, humanAsxl1 protein, mouseHistonesRepressor Proteins

Identifiers

PMID29643185
PMCPMC5987913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.